Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CDKN2A interacting protein N-terminal like pseudogene 1 (CDKN2AIPNLP1) is a pseudogene in the human genome. Pseudogenes are genomic sequences similar to normal genes but are non-functional; they do not encode functional proteins and are not considered typical biological drug or therapeutic targets. There is no evidence in the current literature or genetic databases for a direct role or function of CDKN2AIPNLP1 in biological pathways, disease mechanisms, or as a therapeutic target. Unlike some well-studied pseudogenes with regulatory "decoy" functions (such as PTENP1 regulating PTEN), there is no direct evidence or published data indicating such a regulatory role for CDKN2AIPNLP1. The gene is primarily catalogued as a non-functional DNA sequence and lacks known aliases, functional properties, or clinical relevance. The abbreviation and name both refer to a pseudogene, which by definition is not a conventional molecular target (receptor, enzyme, etc.), lacks protein product, and is generally not considered "druggable." Selection of this entry as a drug target is likely incorrect, as there is no evidence supporting its status as a target for therapy, nor association with drug mechanisms, biomarkers, or safety concerns. If you are seeking information about CDKN2AIP or the canonical CDKN2AIP gene (not the "like pseudogene 1" variant), that is a functional gene and should be queried separately.
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CDKN2A interacting protein N-terminal like pseudogene 1 (CDKN2AIPNLP1).